Today’s Research Reports on Stocks to Watch: Dynavax Technologies and Gigamon
Dynavax Technologies Corporation saw its shares skyrocket on Monday after releasing huge SD-101 results over the weekend. The results showed how well SD-101 had a response rate in metastatic melanoma patients when combined with big giant Merck’s Keytruda. Investors were optimistic about a commercialize agreement possibly being soon in the works. Gigamon also saw its shares soar higher after a report indicated that the company could be up for sale now.
RDI Initiates Coverage on:
Dynavax Technologies Corporation
Dynavax Technologies Corporation shares closed up 16.95% yesterday on tremendous volume compared to usual after the clinical-stage biotech company released important initial results at the 2017 American Society of Clinical Oncology (ASCO) over the weekend. Results from the company’s dose escalation in its phase 1/2 metastatic melanoma trial with intratumoral TLR9 agonist SD-101, combined with Merck’s Keytruda, reported a 100% overall response rate in seven anti-PD-1/L1-nairve patients. There was a complete response rate of 29%. Traders were left encouraged by the results because it could end up leading to a Merck deal later on for commercialization. The combination of SD-101 with Keytruda not only boosted efficacy in metastatic melanoma patients but without an increase in side effects.
Access RDI’s Dynavax Technologies Research Report at:
Gigamon Inc. shares closed up 8.96% on Monday after a report surfaced over the weekend that indicated Gigamon could be putting itself up for sale. According to sources who have not been revealed, Reuters reported that the company has hired Goldman Sachs to engage in acquisition talks with companies and private equity firms who would be interested in purchasing the company. Last month activist hedge fund Elliott Management Corp. announced that it took a 15.3% stake in the monitoring and security software maker. It’s been four years since Gigamon had its IPO. The stock has a market cap of around $1.5 billion today. Analysts at Needham & Co. stated yesterday, “We think the odds have significantly increased that Gigamon could be acquired. We think a fair value is in the 50 to 55 range.” The company has a price target of $50 on Gigamon now. Previously their target was $34.
Access RDI’s Gigamon Research Report at:
Our Actionable Research on Dynavax Technologies Corporation (NASDAQ: DVAX) and Gigamon Inc. (NYSE: GIMO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.